Acneiform dermatitis exhibited the most pronounced difference (86 cases with Cetuximab vs. 5 cases with Nivolumab), with an ROR of 12.31 (95% CI: 9.87–15.32), consistent with the well-documented mechanism of EGFR inhibitor–induced cutaneous toxicity (Figure 2B). This evidence concerns the gene EGFR and acneiform dermatitis.